Umoja Biopharma is reprogramming T cells to target cancer cells. Chimeric antigen receptor (CAR) T-cell immunotherapies have shown promising results for hematologic cancers, but the majority of cancers manifest as solid tumors. Umoja is working to create “off-the-shelf” CAR T-cell immunotherapies for patients with solid tumors that are scalable and less expensive than current approaches. To identify effective CAR T-cell gene therapies, Umoja is pioneering complementary solutions to generate cancer fighting T-cells that reduce adverse events and prolong remission for patients. This includes VivoVec, an in vivo gene delivery platform that enables the body to make its own CAR T-cells. Umoja is combining these platforms to build their pipeline, which includes candidates for multiple indications.